Clinical Trial: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07751133) titled 'Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer' on July 25.

Brief Summary: The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread (metastasized). The main questions it aims to answer are:

1. if overall survival for reduced dose ARPI is not worse than standard dose ARPI when treating patients with metastatic prostate cancer, and

2. that fatigue (extreme exhaustion) and not stopping ARPI permanently (due to adverse effects) are ...